This research investigates the role of oligodendrocytes in Fragile X syndrome, revealing delayed cell maturation and disrupted myelin development. Using human stem cell and mouse models, it identifies these overlooked cells as promising therapeutic targets, potentially enabling earlier and more effective treatments for Fragile X and related neurodevelopmental disorders.

This research shows that early-life oxytocin treatment can reverse key features of fragile X syndrome in mice. Brief intervention strengthens neural connections, normalizes learning and social behavior, and prevents seizures into adulthood. The findings suggest oxytocin may offer a safe, early intervention strategy for fragile X and other intellectual disabilities.

SLC13A5 citrate transport disorder causes severe neonatal seizures due to disrupted citrate balance in the brain. This research uses mouse models to show excess citrate worsens seizures and explores gene replacement therapy to restore transporter function. Early results show reduced seizures, with human clinical trials beginning soon.